Why should we need the gut microbiota to respond to cancer therapies? Academic Article uri icon

Overview

abstract

  • Cyclophosphamide, one of the most efficient tumoricidal, antiangiogenic, and immunostimulatory drugs employed to date mediates part of its effects through intestinal bacteria, against which the host becomes immunized during treatment. Our recent work suggests that anti-commensal effector pTH17 and memory TH1 CD4+ T-cell responses are indispensable for optimal anticancer effects as mediated by cyclophosphamide.

publication date

  • January 17, 2014

Identity

PubMed Central ID

  • PMC4006853

Scopus Document Identifier

  • 84888049920

Digital Object Identifier (DOI)

  • 10.1126/science.1240527

PubMed ID

  • 24800167

Additional Document Info

volume

  • 3

issue

  • 1